Financial Analysis: Mind Medicine (MindMed) (MNMD) vs. Its Rivals

Mind Medicine (MindMed) (NASDAQ:MNMDGet Rating) is one of 49 public companies in the “Medicinals & botanicals” industry, but how does it compare to its rivals? We will compare Mind Medicine (MindMed) to related companies based on the strength of its earnings, dividends, analyst recommendations, profitability, risk, valuation and institutional ownership.

Profitability

This table compares Mind Medicine (MindMed) and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mind Medicine (MindMed) N/A -55.27% -51.10%
Mind Medicine (MindMed) Competitors -178.38% -256.88% -14.34%

Insider & Institutional Ownership

10.8% of Mind Medicine (MindMed) shares are owned by institutional investors. Comparatively, 16.3% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 23.1% of shares of all “Medicinals & botanicals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Mind Medicine (MindMed) and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mind Medicine (MindMed) 0 0 2 0 3.00
Mind Medicine (MindMed) Competitors 262 670 668 25 2.28

Mind Medicine (MindMed) presently has a consensus price target of 8.00, suggesting a potential upside of 724.74%. As a group, “Medicinals & botanicals” companies have a potential upside of 82.99%. Given Mind Medicine (MindMed)’s stronger consensus rating and higher possible upside, analysts plainly believe Mind Medicine (MindMed) is more favorable than its rivals.

Valuation & Earnings

This table compares Mind Medicine (MindMed) and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Mind Medicine (MindMed) N/A -$93.04 million -4.22
Mind Medicine (MindMed) Competitors $238.90 million -$88.70 million -7.73

Mind Medicine (MindMed)’s rivals have higher revenue and earnings than Mind Medicine (MindMed). Mind Medicine (MindMed) is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Mind Medicine (MindMed) Company Profile (Get Rating)

Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.